In vivo jnk activation in pancreatic β-cells leads to glucose intolerance caused by insulin resistance in pancreas

Diabetes

Volumn 62, Issue 7, 2013, Pages 2308-2317

  Lanuza Masdeu, Jordi ^a,b   Isabel Arevalo M ^a,b   Vila, Cristina ^b   Barberà, Albert ^a,c   Gomis, Ramon ^a,c   Caelles, Carme ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; GLUCOSE; INSULIN; ISOBUTYLMETHYLXANTHINE; POTASSIUM CHLORIDE; PROTEIN KINASE B; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; SUCCINIC ACID; TOLBUTAMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CONTROLLED STUDY; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULINEMIA; MALE; MOUSE; NONHUMAN; PANCREAS; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MAP KINASE KINASE 7; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; PANCREAS; THIAZOLIDINEDIONES;

EID: 84882763389     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1097     Document Type: Article

References (43)

1. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415-445
2. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-461
3. Solinas G, Naugler W, Galimi F, Lee MS, Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci USA 2006; 103:16454-16459
4. Solinas G, Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J 2010;24:2596-2611
5. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96
6. Gupta S, Barrett T, Whitmarsh AJ, et al. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J 1996;15:2760- 2770
7. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336
8. Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004;10:1128-1132
9. Díaz-Delfín J, Morales M, Caelles C. Hypoglycemic action of thiazolidinediones/ peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 2007;56:1865-1871
10. Bennett BL, Satoh Y, Lewis AJ. JNK: A new therapeutic target for diabetes. Curr Opin Pharmacol 2003;3:420-425
11. Varona-Santos JL, Pileggi A, Molano RD, et al. c-Jun N-terminal kinase 1 is deleterious to the function and survival of murine pancreatic islets. Diabetologia 2008;51:2271-2280
12. Ammendrup A, Maillard A, Nielsen K, et al. The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic β-cells. Diabetes 2000;49:1468- 1476
13. Kim WH, Lee JW, Gao B, Jung MH. Synergistic activation of JNK/SAPK induced by TNF-alpha and IFN-gamma: apoptosis of pancreatic beta-cells via the p53 and ROS pathway. Cell Signal 2005;17:1516-1532
14. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001; 50:77-82
15. Abdelli S, Ansite J, Roduit R, et al. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes 2004;53:2815-2823
16. Aikin R, Maysinger D, Rosenberg L. Cross-talk between phosphatidylinositol 3-kinase/AKT and c-jun NH2-terminal kinase mediates survival of isolated human islets. Endocrinology 2004;145:4522-4531
17. Fornoni A, Pileggi A, Molano RD, et al. Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads toAKT and glycogen synthase kinase-3 (GSK-3) phosphorylation. Diabetologia 2008;51:298-308
18. Noguchi H, Nakai Y, Matsumoto S, et al. Cell permeable peptide of JNK inhibitor prevents islet apoptosis immediately after isolation and improves islet graft function. Am J Transplant 2005;5:1848-1855
19. Noguchi H, Nakai Y, Ueda M, et al. Activation of c-Jun NH2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor. Diabetologia 2007;50: 612-619
20. Caelles C, González-Sancho JM, Muñoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997;11: 3351-3364
21. Petrich BG, Molkentin JD, Wang Y. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J 2003;17:749-751
22. Lee YH, Giraud J, Davis RJ, White MF. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003;278:2896-2902
23. Kubota H, Noguchi R, Toyoshima Y, et al. Temporal coding of insulin action through multiplexing of the AKT pathway. Mol Cell 2012;46:820-832
24. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002;51: 1507-1514
25. Hernandez R, Teruel T, de Alvaro C, Lorenzo M. Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNFalpha induction of p38 and p42/p44 mitogen-activated protein kinases. Diabetologia 2004;47:1615-1624
26. Yoon SY, Park JS, Choi JE, et al. Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells. Neurobiol Dis 2010;40:449-455
27. Nakatani Y, Kaneto H, Kawamori D, et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004;279: 45803-45809
28. Tuncman G, Hirosumi J, Solinas G, Chang L, Karin M, Hotamisligil GS. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci USA 2006;103:10741- 10746
29. Sabio G, Kennedy NJ, Cavanagh-Kyros J, et al. Role of muscle c-Jun NH2- terminal kinase 1 in obesity-induced insulin resistance. Mol Cell Biol 2010; 30:106-115
30. Zhang X, Xu A, Chung SK, et al. Selective inactivation of c-Jun NH2-terminal kinase in adipose tissue protects against diet-induced obesity and improves insulin sensitivity in both liver and skeletal muscle in mice. Diabetes 2011; 60:486-495
31. Solinas G, Vilcu C, Neels JG, et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007;6:386-397
32. Masharani UB, Maddux BA, Li X, et al. Insulin resistance in non-obese subjects is associated with activation of the JNK pathway and impaired insulin signaling in skeletal muscle. PLoS ONE 2011;6:e19878
33. Kaneto H, Xu G, Fujii N, Kim S, Bonner-Weir S, Weir GC. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. J Biol Chem 2002;277:30010-30018
34. Wicksteed B, Brissova M, Yan W, et al. Conditional gene targeting in mouse pancreatic ß-Cells: analysis of ectopic Cre transgene expression in the brain. Diabetes 2010;59:3090-3098
35. Chan O, Sherwin RS. Hypothalamic regulation of glucose-stimulated insulin secretion. Diabetes 2012;61:564-565
36. Ashcroft FM, Rorsman P. Diabetes mellitus and the b cell: The last ten years. Cell 2012;148:1160-1171
37. Kawamori D, Kajimoto Y, Kaneto H, et al. Oxidative stress induces nucleocytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH(2)-terminal kinase. Diabetes 2003;52:2896- 2904
38. Humphrey RK, Yu SM, Flores LE, Jhala US. Glucose regulates steady-state levels of PDX1 via the reciprocal actions of GXK3 and AKT kinases. J Biol Chem 2010;258:3406-3416
39. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000;275:9047- 9054
40. Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor g agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665- 668
41. Berger J, Bailey P, Biswas C, et al. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-g: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996;137:4189-4195
42. Rosen ED, Kulkarni RN, Sarraf P, et al. Targeted elimination of peroxisome proliferator-activated receptor gamma in beta cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 2003;23:7222-7229
43. Eldor R, Yeffet A, Baum K, et al. Conditional and specific NF-kappaB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci USA 2006;103:5072-5077